SHR-1210 a Novel Anti-pd-1 Antibody, in Combination With BP102,a Biosimilar of Bevacizumab, and XELOX, (Oxaliplatin Plus Capecitabine) in Patient With Metastatic Colorectal Cancer: a Single-arm, Open Label, Multi-center, Phase II Study
Phase of Trial: Phase II
Latest Information Update: 24 Nov 2018
At a glance
- Drugs Camrelizumab (Primary) ; BP 102; Capecitabine; Oxaliplatin
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 14 Nov 2018 Status changed from not yet recruiting to recruiting.
- 31 Aug 2018 New trial record